Allergan Medical
13
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
7.7%
1 terminated/withdrawn out of 13 trials
91.7%
+5.2% vs industry average
15%
2 trials in Phase 3/4
100%
11 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-L® for Lip Volume Enhancement
Role: lead
Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nasolabial Folds
Role: lead
Seri Surgical Scaffold Support of the Lower Pole of the Breast
Role: collaborator
Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants
Role: lead
Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants
Role: lead
European Union (EU) Post-Market Study on Easyband®
Role: lead
Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancement
Role: lead
Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study
Role: lead
Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips
Role: lead
The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face
Role: lead
Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine
Role: lead
EasyBand GOAL Trial
Role: lead
Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy
Role: collaborator
All 13 trials loaded